Abbott Joins Gene Logic’s Stable Of Pharma Partners
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott could pay Gene Logic as much as $100 million in milestones for each drug candidate that is eventually marketed, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Gene Logic Adds Merck Serono To Growing List Of Pharma Partners
Firm seeks a development partner for its internal candidate, GL1001, which has shown indications of efficacy in vivo for inflammatory bowel disease.
Gene Logic Adds Merck Serono To Growing List Of Pharma Partners
Firm seeks a development partner for its internal candidate, GL1001, which has shown indications of efficacy in vivo for inflammatory bowel disease.
Gene Logic Adds Lilly To Its Drug Rescue Roster
Company will reconsider drug candidates that were “discontinued or de-prioritized” for non-safety reasons and could even license them if Lilly opts out.